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Abstract: Here, we reviewed emerging evidence on the role of the microbial community in colorectal
carcinogenesis. A healthy gut microbiota promotes intestinal homeostasis and can exert anti-cancer
effects; however, this microbiota also produces a variety of metabolites that are genotoxic and which
can negatively influence epithelial cell behaviour. Disturbances in the normal microbial balance,
known as dysbiosis, are frequently observed in colorectal cancer (CRC) patients. Microbial species
linked to CRC include certain strains of Bacteroides fragilis, Escherichia coli, Streptococcus gallolyticus,
Enterococcus faecalis and Fusobacterium nucleatum, amongst others. Whether these microbes are merely
passive dwellers exploiting the tumour environment, or rather, active protagonists in the carcinogenic
process is the subject of much research. The incidence of chemically-induced tumours in mice models
varies, depending upon the presence or absence of these microorganisms, thus strongly suggesting
influences on disease causation. Putative mechanistic explanations differentially link these strains
to DNA damage, inflammation, aberrant cell behaviour and immune suppression. In the future,
modulating the composition and metabolic activity of this microbial community may have a role in
prevention and therapy.
Keywords: colorectal cancer; microbiota; Fusobacteria; Bacteroides; Streptococcus Gallolyticus;
Escherichia coli; genotoxicity; gut
1. Introduction
The distinguishing characteristic of the colon is the relative abundance of the resident microbiota.
Microbial communities present elsewhere in the GI tract are much smaller and show lower diversity.
In parallel, the comparative incidence of colorectal to oesophageal and stomach cancers is approximately
30:1:2 [1,2]. Germ-free mice demonstrate the importance of host-microbe interactions to healthy host
physiology; in these models, the colon architecture is visibly aberrant, there is an under-developed
immune system [3], poor wnt signalling mediated differentiation of epithelial cells [4] and a functionally
impaired epithelial barrier [5]. Further, the incidence of chemically induced tumours in mice models
varies, depending upon the presence or absence of a functional microbiota [6].
Experimental intervention studies in non-germ-free animal models, with both probiotics and
prebiotics, have been shown to suppress tumour development via diverse mechanisms. Several
meta-analyses show that consuming a high-fibre diet reduces colorectal cancer (CRC) risk [7–9]. Fibre
intake may be coupled to saccharolytic microbial activity in the gut and, in particular, the in situ
synthesis of butyrate, with its well-studied anti-neoplastic activity. Thus, these strands of evidence
indicate the importance of a healthy microbiota in cancer suppression. In contrast, we reviewed here
the emerging evidence of the role of the microbial community in promoting colorectal carcinogenesis.
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2. The Healthy Microbiota
In a healthy host, the colonic microbiome is typically dominated, at the phyla level,
by Gram-negative Bacteroidetes and Gram-positive Firmicutes, with a smaller but sizable abundance of
Actinobacteria and Verrucomicrobia [10,11]. The proportions of these phyla are not fixed, and different
phyla, and indeed families, strains and species, compete to fulfil distinct ecological niches. Thus,
under the influences of age, gender, genetics, diet and disease, there is considerable scope for
inter-individual variation between phenotypically similar and healthy individuals [12]. Microbial
diversity between individuals does not appear to critically influence central pathways in microbial
metabolism. The fermentation of carbohydrates generally yields short-chain fatty acids, which can be
used by the host, whilst proteolytic fermentation also yields phenols, cresols, ammonia and sulphides,
commonly thought of as toxins. The production of specific secondary metabolites with pro and/or
anti-carcinogenic activities, such as enterotoxins, cyclomodulins, B vitamins, urolithins, the estrogenic
equol and mammalian lignans, may, however, be dependent on the abundance of certain strains,
or functional groups, of bacteria. Equol, for example, is associated with a reduced risk of CRC [13],
but is produced by fewer than 50% of the population and is dependent on colonisation with a handful
of daidzein metabolising species [14].
3. The Microbiological Environment in Colorectal Cancer
Colorectal cancer has at least four recognised distinct common molecular subtypes [15]. Broadly
speaking, cancers in the descending colon and rectum demonstrate high levels of chromosomal
instability (CIN) and a strong up-regulation of wnt signalling [16]; in contrast, cancers of the ascending
colon are rarer and are more likely to be of the microsatellite instability (MSI) subtype. Thus, the favoured
anatomical distribution of these tumour sub-types hints at distinct aetiologies [17]. The right and left
side of the colon have different embryological origins, but physiologically, these sections of the colon
may be characterised as having distinct microbial activities. Saccharolytic fermentation dominates in
the ascending colon, where the high fluid volume may also make the luminal contents quite dilute [18].
Microbial metabolites produced in the caecum, including short-chain fatty acids, may be reabsorbed,
with water and electrolytes, in situ and through the transverse colon, such that the contents of the
descending colon are more concentrated in biomass and potentially in toxic metabolites. In in vitro
models, total microbial activity appears to decrease in the latter portions of the bowel and proteolysis
becomes favoured [19,20]. Thus, distal and proximal colonocytes may be exposed to quite different
microbial metabolites. To this point, these gradients in exposures have been poorly considered in
relation to tumour subtype. Perhaps problematically, the aetiological/epidemiological studies continue
to view CRC as a single disease, and therefore going forward, we will need to better consider tumour
site and subtype in relation to diet and microbial exposures.
4. Microbial Metabolism in Carcinogenesis
Yachida et al. [21] compared the abundance of microbial metabolism genes present in stool between
healthy controls and volunteers at different stages of the colorectal cancer process. In volunteers
with preneoplastic polyps, they noted an increase in the abundance of genes involved in amino acid
and sulphur metabolism and a relative decrease in the abundance of genes involved in methane
metabolism. This is consistent with the long-standing assumption that a gut microbial environment
favouring proteolytic over saccharolytic fermentation may increase CRC risk. With a western diet,
somewhere between 6 and 18 g of protein per day is thought to reach the colon [22,23]. With decreasing
availability of fermentable carbohydrate in the distal colon, there is a shift towards the production of
proteolytic end products in the more cancer-prone left side [24]. In in vitro mixed culture models of
gut fermentation, increasing protein concentrations in culture media leads to elevated production of
phenolic compounds, amines, ammonia and hydrogen sulphide. These metabolites can be leveraged
as nitrogen sources for bacterial cross-feeding, or they may be taken up by colonocytes and transported
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into the bloodstream [25]; however, their accumulation in the colonic lumen is associated with increased
epithelial cell toxicity [26,27].
The amino acid composition of the protein substrate influences the overall composition of this
potentially genotoxic fermentation supernatant. For example, methionine and cysteine may be used as
a substrate by the sulphate-reducing bacteria (SRB) (i.e., Desulfovibrio, Desulfotomaculum, Desulfobacter,
Desulfobulbus [28]), leading to the generation of H2S [28,29]. Hydrogen sulphide inhibits butyric acid
oxidation [30–32], it increases cell proliferation in vitro [33] and is shown to be genotoxic [34]. In in vitro
batch-culture fermentation with faecal inoculate, the rate of H2S production differs according to whether
albumin or casein is used as a substrate [35]. In human observational studies, the sulphate reducing
bacteria may be associated with inflammatory bowel disease [36] and are putatively implicated in its
pathogenesis through the ability of H2S to compromise barrier function [29,37]. In both animal and
human dietary intervention study, diets high in protein increase the recovery of sulphide in faeces [38],
and Yachida et al. [21] observed an increase in the abundance of sulphate-reducing bacteria in stool
samples from stage II and III cancer patients versus healthy controls.
Fermentation of aromatic amino acids leads to the production of phenols, indoles and 4-cresol.
These are not well recovered in stool, but rather enter the hepatic circulation to be detoxified in the liver
and eventually excreted in urine [39]. Studies have shown that with high protein intake, metabolites of
4-cresol and phenol appear in the urine [40]. Phenol and 4-cresol reach genotoxic concentrations in the
in vitro gut fermentation models, which vary according to a protein source, and their concentration
can be used to predict the genotoxicity of gut fermentation supernatants [41].
In contrast to the epidemiological data, the carcinogenicity of higher protein diets is consistently
demonstrated, particularly in relation to colonic inflammation, in experimental animal models [42].
Higher protein dietary interventions in human volunteers lead to increased urinary excretion of markers
of amino acid fermentation, but the appearance of these metabolites in urine does not necessarily
correlate with increased faecal water genotoxicity [43,44]. Colonic fermentation and absorption
are dynamic; therefore, faecal samples may be poorly representative of colonic exposures. Better
biomarkers of cancer risk for human dietary intervention study are certainly needed to bridge the
gap between the lack of associations between protein intake and cancer in human subjects versus the
mechanistic and animal experimental evidence, implicating proteolytic gut fermentation metabolites
in CRC.
5. The Colon Cancer Specific Microbiota
The tumour environment may be characterised by a disruption to the colonic stream, a depleted
mucosal barrier, altered mucin secretion, inflammation, and changes in secretory IgA release that may
facilitate aberrant biofilm formation. There may also be potential changes to the intestinal substrate
in the form of blood, mucins, and host-derived lactate as a glycolytic metabolic by-product. Thus,
specialists within the biota could well thrive as passengers in this ecological niche. The identification
of tumour-specific microbes present in mucosal and/or faecal samples, and absent in healthy
controls [45–48], or tumour tissue versus the adjacent healthy mucosa [49–53], prompts investigation
into their precise role in disease aetiology. Enterotoxic strains of Bacteroides fragilis, PKS+ve strains of
Escherichia Coli, Fusobacterium nucleatum, Enterococcus faecalis and Streptococcus gallolyticus are candidate
tumour-associated microbial species considered here for their roles in disease causality.
Streptococcus gallolyticus: Endocarditis and bacteraemia associated with Streptococcus gallolyticus
(Sg) infection are associated with increased risk of colorectal neoplasia in observational studies [54,55].
Further, case-control studies show an increased risk of colorectal cancer associated with serological
evidence of previous exposure to (Sg) antigen [56]. Faecal samples from volunteers with colorectal
cancer are more likely to score positively for Sg, and tumour tissues show higher Sg counts than
adjacent normal mucosa.
Experimentally, pre-exposure of cultured HCT116 cells to Sg prior to implantation resulted in
the subsequent growth of a greater tumour mass in a mouse xenograft model. Further, oral gavage
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with Sg increased the tumour burden in AOM and DSS mouse models of tumorigenesis [57–59]. From
a mechanistic perspective, Abdulamir et al. [60] observed a higher expression of Nf-KB and IL-8
mRNA in tumour tissues from individuals seropositive for Sg antibodies versus Sg negative patients,
suggesting the Sg exposure induces a pro-inflammatory state, which may be a driver of cell turnover
and is thus tumour promoting. However, Kumar et al. [57] observed increased cell proliferation in
cultured colon cancer cell lines (HT29, HCT116 and LoVo) exposed to Sg and demonstrated that this
was driven by an increase in nuclear β-catenin independent of inflammation. Further, there is evidence
to suggest that the degree of tumorigenicity of individual sub-strains of Sg is dependent upon their
ability to bind to intestinal epithelial cells [61]. Thus, adherent Sg may directly stimulate epithelial cell
turnover through some, as yet not fully elucidated, cellular cross-talk.
Enterococcus faecalis: E. faecalis is closely related to S. gallolyticus; it has been associated with
colitis [62] and colorectal cancer in observational studies [63,64]. Mechanistically, E. faecalis induces
colitis in experimentally susceptible animal models [65,66]; however, experiments with cultured
epithelial cells suggest that it may mediate the cancer process more directly through the production
of genotoxic peroxide [67] and through its influences on cell cycle behaviour and the precipitation of
polyploidy [68]. Recently, Lennard et al. [63] noted the greater expression of metastasis-associated
genes in E. faecalis positive tumour tissue compared to non-EF colonised tumours, although follow on
studies are yet to confirm this potential effect.
Escherichia coli: Raisch et al. [69] studied the abundance of E. coli by phylogenetic subgroup
in mucosal biopsies from colorectal cancer versus mucosal samples from patients with diverticular
disease as a control. They reported a much higher abundance of E. coli from the phylogenetic subgroup
B2 in the cancer patient specimens (positively identified in 73.7% of cancer specimens versus 41.9%
of controls). The phylogenetic B2 subgroup is home to enteropathogenic E. coli strains that are
frequently associated with inflammatory bowel disease [62]; Fang et al. [70] observed specialist mucin
degrading metabolic apparatus amongst the B2 E. coli, which may contribute to their colonisation
and the pathogenesis of IBD. This group may also be characterised by the presence of genes encoding
cyclomodulins, and genotoxins, such as colibactin. Cycle inhibiting factor (CIF) is a cyclomodulin
capable of blocking mitosis independently of DNA damage, at least in vitro [71], and of inducing
apoptosis in exposed epithelial cell lines [72]. In contrast, cytotoxic necrotising factor (CNF-1) exposure
precipitates a reorganisation of the actin cytoskeleton and reversible cellular senescence that may be
coupled to chromosomal irregularities and genomic instability in cultured colonocytes [73].
Colibactin is a poorly characterised genotoxic polyketide-peptide produced in the gut by polyketide
synthase (PKS) positive E. coli [74]. These PKS positive bacteria have been identified in up to 20% of
healthy volunteers. In animal models of carcinogenesis, exposure to PKS may induce DNA strand
breaks [75] and tumour formation [76,77]. Transient infection of cultured epithelial cells with PKS
positive E. coli induces chromosomal aberrations and increases the mutation frequency rate [75],
in addition to influencing cell cycle behaviour [78].
Bacteroides fragilis: Perhaps up to 40% of the healthy population harbour intestinal strains
of B. fragilis that are capable of producing a metalloproteinase enterotoxin (BFT). BFT+ B. fragilis
colonisation has been associated with early neoplastic changes (adenoma and serrated polyps),
but not necessarily in patients shown to have carcinoma [79,80], which might suggest a role in
early carcinogenesis.
In mice, colonisation with BFT+ B. fragilis is capable of inducing Th-17-mediated colitis [81]
and distal colorectal cancers in the APCmin mouse model in a manner dependent on IL17 mediated
up-regulation of NF-κb, as demonstrated by Chung et al. [82] who observed repressed BFT-induced
tumour formation in APCmin IL17/IL17 mice. Further, Geis et al. [83] observed an accumulation of TReg
cells in the APCmin mouse post-BFT colonisation, which may be the trigger for an IL17-mediated
pro-carcinogenic inflammatory response.
Cultured epithelial cell models suggest alternative, or indeed complimentary, pro-carcinogenic
mechanisms, the BFT toxin induces cleavage of E-Cadherin, leading to increased paracellular
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permeability and the activation of β-Catenin and a subsequent increase in cell proliferation [84],
and it has been associated with polyamine metabolism-associated DNA damage when applied to
cultured Ht29 and T80 cells [85]
It is also feasible that BFT+ B. fragilis facilitates localised microbial dysbiosis that indirectly facilitates
carcinogenesis through the enabling of other pro-carcinogenic bacteria, both through its effects on
the host immune apparatus [83] and potentially also through its effect on the gut barrier [84] and its
recently reported influence on Muc2 synthesis and its well established role in mucin degradation [86].
Indeed, Dejea et al. [87] recently observed an abundance of biofilms co-colonised with BFT+ B. fragilis
and PKS+ E. coli amongst FAP patients relative to healthy controls. They went on to demonstrate
increased tumour lethality in co-colonised AOM-induced mice. Elsewhere, Drewes et al. [88] identified
polymicrobial biofilms enriched with BFT+ B. fragilis and Fusobacterium nucleatum in 38 of 40 right-sided
colorectal tumours but only 14 of 51 left-sided tumours. Tomkovich et al. [89] demonstrated that
inoculation of APC min IL10-/- mice with polymicrobial biofilms isolated from tumour specimens
induced tumours in the mice, importantly the BFT+ polymicrobial biofilms were more likely to induce
inflammation in the mouse distal colon than BFT− samples. Interestingly, they also showed that a
minority of healthy volunteers harboured colonic biofilms capable of inducing tumours in this model.
This may have clinical implications for a faecal transplant, and further, given that we have limited
direct proof of cancer causation, this group might warrant monitoring for future risk of colorectal
cancer, and be leveraged for study in polyp recurrence studies.
Fusobacterium nucleatum is an oral symbiont, and occasional pathogen that has been identified in,
and cultured from, intestinal tumours [50,90–93]. Yachida et al. [21] observed a progressive increase in
the prevalence of F. nucleatum through the cancer stages beginning with highly dysplastic adenomas,
whilst Amitay et al. [94] were unable to identify F. nucleatum in pre-neoplastic adenomas, suggesting
that F. nucleatum is not a tumour initiator, but rather, an opportunistic coloniser during disease
progression. Moreover, evidence suggests that F. nucleatum may be particularly associated with MSI
and CIMP positive tumours [95]. Importantly, colonisation with FN has been associated with shorter
survival in cancer patients in five out of 10 studies, as reviewed eloquently by Liu et al. [96], whilst in
cultured cells, Rubinstein et al. [93] observed that F. nucleatum stimulates the proliferation of a panel of
transformed colorectal cancer cell lines but not the non-cancerous (HEK293) cell line. In APCmin/+ mice,
inoculation with F. nucleatum induced the growth of significantly more tumours than in controls, whilst
pre-treatment of tumour cells with F. nucleatum also induced significantly more tumours in a xenograft
model [97]. Thus, in mice, F. nucleatum acts as a tumour promoter or enabler. A variety of potential
tumour promoting mechanisms arebeing investigated. Tomkovich et al. [76,98] noted no increase in
inflammation, in tumour susceptible APCMin/+;Il10−/− and APCMin/+ germ-free animals colonised with
F. nucleatum, suggesting that F. nucleatum does not promote tumourigenesis via inflammation-related
pathways. Evidence is instead pointing to direct E-cadherin-mediated interactions with the epithelial
cell wnt signalling pathway, thus promoting cell proliferation [93,97,99], and through suppression of
immune surveillance [92,100,101].
6. Conclusions
Candidate tumour-associated microbes are still being identified. Here, we focused on those
microbes best characterised in relation to CRC. These microbes are useful in that they demonstrate
various roles for gut bacteria in different carcinogenic pathways across inflammation, immune
suppression and through direct modulation of host cell behaviour. The proof of cancer causality for
each of these microbes, in man, remains indirect; strong mechanistic studies are emerging to explain the
observational associations with disease, as are studies showing causation in animal models (Table 1).
Characterisation of banked stool samples from prospective cohort studies would strengthen the current
evidence base further.
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Table 1. Mechanistic evidence underpinning the putative role of tumour-associated gut bacteria in colorectal carcinogenesis. + suggestive evidence, ++ multiple
strands of evidence.
IBD
Associated
Immuno-
Suppressive
Pro-
Inflammatory
CHROMOSOMAL
instability
MSI
Associated
CIMP
Associated
DNA Damage
Induction in
Cultured
Colonocytes
Proliferation
Influence
over Cultured
Colonocytes
Metastasis
Influencing
Streptococcus
gallolyticus ++ ++
Enterococcus
faecalis ++ ++ ++ ++ ++ +
CIF +ve
Escherichia coli ++ ++
CNF +ve
Escherichia coli + ++
Colibactin +ve
Eschericia coli ++ ++ ++
BFT+ve
Bacteroides
fragilis
++ ++ ++ ++
Fusobacterium
nucleatum ++ ++ ++ ++
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Questions also persist about the role of these tumour-associated microbes in different subtypes of
CRC; F. nucleatum, for example, maybe more strongly associated with serrated adenomas [102,103],
and BFT+ve biofilms appear to dominate in right-sided tumours [88]. These observations may be a
consequence of the wider gradient in microbial metabolic activity through the colon favouring certain
bacteria in the ceacum; alternatively, it may be a reflection of higher toxic concentrations in the sigmoid
colon favouring the chemically-induced mutations classically associated with the adenocarcinoma
sequence. Future interventions aimed at modulating gut microbial metabolism in relation to CRC risk
in man might also take into account differential drivers for specific tumour type and location. Important
questions also remain about the role of specific microbiota at different stages of the cancer process.
In the future, targeted removal of early-stage carcinogenic members of the gut microbial community,
perhaps with phage or other approaches, might be a desirable approach to reducing risk factors for
cancer. Early-stage CRC-associated bacteria might also be useful as biomarkers of disease risk. On the
other hand, transient colonisers, contributing later in the carcinogenic process, might be important
drug targets, or where they are favourably adherent to tumour tissue they may have the potential for
leverage as drug delivery vehicles.
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